<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736772</url>
  </required_header>
  <id_info>
    <org_study_id>14828</org_study_id>
    <secondary_id>I6M-JE-SSAA</secondary_id>
    <nct_id>NCT03736772</nct_id>
  </id_info>
  <brief_title>A Study of LY3090106 in Japanese and Caucasian Healthy Participants</brief_title>
  <official_title>A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of a study drug known as LY3090106
      in healthy Caucasian and Japanese participants. Side effects and tolerability will be
      documented. Blood samples will be taken to compare how the body handles the drug. The study
      will last about 12 weeks, not including screening or additional follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Actual">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">March 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) of LY3090106</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>Cmax of LY3090106</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Versus-Time Curve (AUC) of LY3090106</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>AUC of LY3090106</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3090106</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3090106 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3090106</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3090106</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy Japanese or Caucasian

          -  Body mass index (BMI) 18.0 - 32.0 kilograms per square meter (kg/mÂ²)

        Exclusion Criteria:

          -  Have participated, within the last 30 days, in a clinical study involving an
             investigational product (IP). If the previous IP has a long half-life, 5 half-lives or
             30 days (whichever is longer) should have passed

          -  Have had symptomatic herpes zoster within 3 months of screening

          -  Show evidence of active or latent tuberculosis (TB)

          -  Have known hypogammaglobulinemia or a screening serum immunoglobulin (Ig) G &lt;565
             milligrams per deciliter (mg/dL)

          -  Have received live or attenuated vaccine(s) within 1 month of screening, or intend to
             during the study

          -  Are immunocompromised

          -  Have received treatment with biologic agents (such as monoclonal antibodies, including
             marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
             Participants with any prior exposure to ixekizumab, tabalumab or other biologic agents
             directly targeting Interleukin 17 (IL-17) and/or B cells (e.g., rituximab, belimumab,
             etc.) are excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1, 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

